Pulmonology

Updates to CDC recommendations on influenza and COVID-19 vaccines and vaccine formulations will impact your choices during flu season this year.

The ACIP was unanimous in its recommendation for routine use of nirsevimab-alip to prevent RSV LRTD in newborns and young infants during their first RSV season.

Statistically significant positive immune responses were observed in both vaccine-naive adults and those previously vaccinated, including for the vaccine's 8 unique serotypes.

The arrival of COVID-19 vaccines challenged many people for the first time to understand the actual public health role of vaccination. With the RSV shots, it may be round 2.

The triple assay can identify and differentiate influenza, COVID-19, and respiratory syncytial virus in approximately 2 hours and is already in use.

ACIP guidance on influenza vaccination for the 2023-2024 respiratory virus season includes updates important for primary care clinicians.

The real-world analysis measured the benefit of primary vaccination and of a booster and found the latter dependent upon local disease incidence and risk for severe disease.

A daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Nirsevimab won unanimous support from the FDA AMDAC on the vaccine's positive benefit/risk profile to prevent RSV in newborns and infants in their first RSV season.

Findings from meta-analysis showed preoperative high-intensity interval training was associated with improvements in exercise capacity and a reduction in postoperative complications.

The influenza vaccine may offer a protective effect against hospitalization for respiratory syncytial virus in young children, suggest data from Australia.

In the post COVID-19 pandemic health care emergency era, private and public insurance entities will continue full coverage of the shots - but what about the uninsured?

Sales of e-cigarettes in the US jumped by 46% from 2020-2022; rapid market shifts beg coordinated restrictions to protect public health, says the CDC.

The FDA's VRBPAC members were unanimous in their recommendation that the 2023-24 COVID vaccines reflect the dominant strain in circulation, XBB.

Patients with diabetes had a 35% higher risk of COPD compared with those without diabetes, according to new research.

Your daily dose of clinical news you may have missed.

Results of a new study offer additional support for clinical guidelines to favor one therapy over another, authors suggest.

The FDA has approved 2 vaccines against respiratory syncytial virus in older adults—with final details pending. This 2-question quiz tests how closely you've been following.

FDA fast tracks triple-threat antithrombotic, dangers of faux semaglutide online, a guide to neurologic sequelae of COVID-19, plus 2 more reviews of note.

Need more talking points to help patients grasp the importance of the bivalent COVID-19 vaccine? The answers to these 3 questions should help.

Nirsevimab, a long-acting monoclonal antibody, if approved, will be indicated to prevent RSV LRTD in neonates and infants born during or entering into their first RSV season.

Children hospitalized for RSV with LRTI during infancy have increased symptoms and lung function abnormalities, including increased resistance and decreased compliance.

Primary care clinicians will often be the first challenged to recognize neurologic sequelae of COVID-19; here's how to maximize short visits to assess long COVID.

Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.